Floatz logo

cx-8998

Tremor

Jazz PharmaceuticalsPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Tremor cohort.

Asset / SponsorPhaseRating
Istradefylline
Georgetown University
Phase 4BB
Xeomin®
Melbourne Health
Phase 3B
INCOBOTULINUMTOXINA
Yale University
Phase 2B
Suvecaltamide
Jazz Pharmaceuticals
Phase 2B
Bont-A
Western University, Canada
Phase 2CCC

View all 10 →

Same molecule, other indications

cx-8998 is also rated in:

epilepsyDormant
CCC
Indicative ·
54 / 100
View asset →
Parkinson diseaseDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →